EP0403360A3 - Verwendung von Phenylethanolaminen zur Herstellung von Medikamenten gegen Augenleiden - Google Patents

Verwendung von Phenylethanolaminen zur Herstellung von Medikamenten gegen Augenleiden Download PDF

Info

Publication number
EP0403360A3
EP0403360A3 EP19900401606 EP90401606A EP0403360A3 EP 0403360 A3 EP0403360 A3 EP 0403360A3 EP 19900401606 EP19900401606 EP 19900401606 EP 90401606 A EP90401606 A EP 90401606A EP 0403360 A3 EP0403360 A3 EP 0403360A3
Authority
EP
European Patent Office
Prior art keywords
preparation
phenylethanolamines
medicament
ophthalmologic disorders
treating ophthalmologic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19900401606
Other languages
English (en)
French (fr)
Other versions
EP0403360B1 (de
EP0403360A2 (de
Inventor
Luciano Manara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi SA
Midy SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8907817A external-priority patent/FR2648043B1/fr
Priority claimed from FR8907816A external-priority patent/FR2648042B1/fr
Application filed by Sanofi SA, Midy SpA filed Critical Sanofi SA
Publication of EP0403360A2 publication Critical patent/EP0403360A2/de
Publication of EP0403360A3 publication Critical patent/EP0403360A3/de
Priority to US07/905,483 priority Critical patent/US5312961A/en
Application granted granted Critical
Publication of EP0403360B1 publication Critical patent/EP0403360B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP90401606A 1989-02-14 1990-06-12 Verwendung von Phenylethanolaminen zur Herstellung von Medikamenten gegen Augenleiden Expired - Lifetime EP0403360B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/905,483 US5312961A (en) 1989-02-14 1992-06-29 2-amino-7-hydroxytetralin carboxylalkyl ethers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8907816 1989-06-13
FR8907817 1989-06-13
FR8907817A FR2648043B1 (fr) 1989-06-13 1989-06-13 Utilisation de phenylethanolamines pour la preparation de medicaments pour les affections oculaires
FR8907816A FR2648042B1 (fr) 1989-06-13 1989-06-13 Utilisation de phenylethanolaminotetralines pour la preparation de medicaments pour le traitement des affections oculaires

Publications (3)

Publication Number Publication Date
EP0403360A2 EP0403360A2 (de) 1990-12-19
EP0403360A3 true EP0403360A3 (de) 1992-02-26
EP0403360B1 EP0403360B1 (de) 1996-10-16

Family

ID=26227393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90401606A Expired - Lifetime EP0403360B1 (de) 1989-02-14 1990-06-12 Verwendung von Phenylethanolaminen zur Herstellung von Medikamenten gegen Augenleiden

Country Status (6)

Country Link
US (1) US5236951A (de)
EP (1) EP0403360B1 (de)
JP (1) JP2844109B2 (de)
AT (1) ATE144139T1 (de)
DE (1) DE69028877T2 (de)
DK (1) DK0403360T3 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2669821A1 (fr) * 1990-12-04 1992-06-05 Sanofi Sa Utilisation de phenylethanolaminotetralines pour la preparation de medicaments destines au traitement de la depression.
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
US5629345A (en) * 1993-07-23 1997-05-13 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5965620A (en) * 1993-07-23 1999-10-12 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
WO1997005091A1 (en) * 1995-07-26 1997-02-13 Ono Pharmaceutical Co., Ltd. Naphthyloxyacetic acid derivatives and drugs comprising the same as active ingredients
US6197993B1 (en) 1996-07-02 2001-03-06 Ono Pharmaceutical Co., Ltd. Naphthyloxyacetic acid derivatives and a pharmaceutical composition comprising them as an active ingredient
US5693216A (en) * 1996-06-03 1997-12-02 Betzdearborn Inc. Method of and composition for breaking oil and water emulsions in crude oil processing operations
RU2116070C1 (ru) * 1996-07-08 1998-07-27 Севиньдж Исмаил кызы Акберова Фармацевтическая композиция
WO2007108541A1 (ja) * 2006-03-23 2007-09-27 Senju Pharmaceutical Co., Ltd. キサンタンガムおよびブドウ糖を含有する眼科用組成物
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040915A1 (de) * 1980-05-22 1981-12-02 Beecham Group Plc Arylethanolamin-Derivate, ihre Herstellung und Verwendung in pharmazeutischen Zusammensetzungen
EP0255415A2 (de) * 1986-06-27 1988-02-03 Elf Sanofi Verwendung von Phenylethanolaminen zur Herstellung von Arzneimitteln, wirksam für gastrointestinale Beschwerden

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808317A (en) * 1969-10-29 1974-04-30 Alcon Labor Inc Stabilized aqueous borate complexes of biologically active catechol amines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040915A1 (de) * 1980-05-22 1981-12-02 Beecham Group Plc Arylethanolamin-Derivate, ihre Herstellung und Verwendung in pharmazeutischen Zusammensetzungen
EP0255415A2 (de) * 1986-06-27 1988-02-03 Elf Sanofi Verwendung von Phenylethanolaminen zur Herstellung von Arzneimitteln, wirksam für gastrointestinale Beschwerden

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"PHARMAKOLOGIE UND TOXIKOLOGIE", 1983, 4 édition, éditeur W. Forth et al., pages 94-95, B.I.-Wissenschaftsverlag; *
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 100, nos. 3-4, 1984, éditeur D. De Wied, pages 309-319, Elsevier Science Publishers B.V., Amsterdam, NL; C. WILSON et al.: "The rat lipolytic beta-adrenoceptor: Studies using novel beta-adrenopceptor agonists" *
FIDIA RESEARCH FOUNDATION SYMPOSIUM SERIES, vol. 2, 'Neurochemical Pharmacology', May 1989, pages 131-147, Raven Press, New York, US; L. MANNARA et al.: "New developments in beta-adrenergic mediated control of intestinal motility: Gut-specific phenylethanolaminotetralines" *
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 6, no. 6, novembre/décembre 1984, pages 1216-1221, Raven Press, New York, US; C. WILSON et al.: "Beta-adrenoceptor subtypes in human, rat, guinea pig, and rabbit atria" *
LIFE SCIENCES, vol. 35, no. 12, 17 septembre 1984, pages 1301-1309, Pergamon Press Ltd, US; S. WILSON et al.: "Genetically obese C57BL/6 ob/ob mice respond normally to sympathomimetic compounds" *

Also Published As

Publication number Publication date
EP0403360B1 (de) 1996-10-16
EP0403360A2 (de) 1990-12-19
DE69028877T2 (de) 1997-02-27
JPH0331212A (ja) 1991-02-12
ATE144139T1 (de) 1996-11-15
DE69028877D1 (de) 1996-11-21
DK0403360T3 (da) 1997-04-07
US5236951A (en) 1993-08-17
JP2844109B2 (ja) 1999-01-06

Similar Documents

Publication Publication Date Title
US4915684A (en) Method and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus
Harris Cycloplegic-induced intraocular pressure elevations: a study of normal and open-angle glaucomatous eyes
DE60022544D1 (de) Behandlung von augenerkrankungen
ATE289815T1 (de) Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
Lass et al. Timolol therapy in secondary angle-closure glaucoma post penetrating keratoplasty
Mapstone Pigment release.
Coppeto et al. Neovascular glaucoma and carotid artery obstructive disease
Ruiz et al. Effects of carbachol and acetylcholine on intraocular pressure after cataract extraction
US6534082B1 (en) Method of treating disorders of the eye
RU93030389A (ru) Средство, восстанавливающее функцию сетчатой оболочки глаза
DK0403360T3 (da) Anvendelse af phenylethanolaminer til fremstilling af et lægemiddel mod øjenlidelser
AASVED et al. Timolol maleate in treatment of open angle glaucoma
Harris et al. Cycloplegic provocative testing: Effect of miotic therapy
Hung Provocation and medical treatment in post-iridectomy glaucoma
EP0305277A3 (de) Verwendung von 2-Amino-6-trifluormethoxybenzthiazol zur Herstellung eines Arzneimittels zur Behandlung von Schlafstörungen und Depressionen
Hong et al. Effect of apraclonidine hydrochloride on the attack of Posner-Schlossman syndrome.
RU2071302C1 (ru) Способ иммунокоррекции при офтальмопатиях
Tingey et al. The effect of intracameral ethacrynic acid on the intraocular pressure of living monkeys
RU2135132C1 (ru) Способ хирургического лечения глаукомы
COLE et al. Evaluation of 100 eyes with traumatic hyphema: intravenous urea
FR2644060B1 (fr) Medicament, notamment pour le traitement de maladies a virus du type herpes cutane, oculaire et genital
Jay et al. Effect of digital massage on intraocular pressure and ocular and optic nerve blood flow
Weber et al. Central retinal vein occlusion and malignant glaucoma
Harbin Jr et al. Applanation-Schiøtz Disparity afrer Retinal Detachment Surgery Utilizing Cryopexy
US5499065A (en) Device for preventing eye drops from entering the nasolacrimal duct system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19901224

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

Owner name: MIDY S.P.A.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MIDY S.P.A.

Owner name: SANOFI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK FR GB IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MIDY S.P.A.

Owner name: ELF SANOFI

17Q First examination report despatched

Effective date: 19940722

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MIDY S.P.A.

Owner name: SANOFI

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 144139

Country of ref document: AT

Date of ref document: 19961115

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

ITF It: translation for a ep patent filed
GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19961029

REF Corresponds to:

Ref document number: 69028877

Country of ref document: DE

Date of ref document: 19961121

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: SANOFI

Owner name: SANOFI WINTHROP S.P.A.

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: SANOFI

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Free format text: SANOFI TRANSFER- SANOFI-SYNTHELABO

NLS Nl: assignments of ep-patents

Owner name: SANOFI-SYNTHELABO

BECA Be: change of holder's address

Free format text: 20000928 *SANOFI-SYNTHELABO;*MIDY S.P.A.:174 AVENUE DE FRANCE, 75013 PARIS;VIA PIRANESI 38, I-20137 MILANO (IT)

BECH Be: change of holder

Free format text: 20000928 *SANOFI-SYNTHELABO;*MIDY S.P.A.:174 AVENUE DE FRANCE, 75013 PARIS;VIA PIRANESI 38, I-20137 MILANO (IT)

BECN Be: change of holder's name

Effective date: 20000928

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: SANOFI-AVENTIS

Free format text: SANOFI-SYNTHELABO#174, AVENUE DE FRANCE#75013 PARIS (FR) -TRANSFER TO- SANOFI-AVENTIS#174, AVENUE DE FRANCE#75013 PARIS (FR)

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: SANOFI -AVENTIS

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20090603

Year of fee payment: 20

Ref country code: DK

Payment date: 20090615

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20090605

Year of fee payment: 20

Ref country code: IT

Payment date: 20090617

Year of fee payment: 20

Ref country code: AT

Payment date: 20090615

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090619

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20090615

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090610

Year of fee payment: 20

Ref country code: DE

Payment date: 20090604

Year of fee payment: 20

Ref country code: LU

Payment date: 20090720

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20100612

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

BE20 Be: patent expired

Owner name: S.A. *SANOFI-AVENTIS

Effective date: 20100612

Owner name: *MIDY S.P.A.

Effective date: 20100612

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20100611

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100612

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20090611

Year of fee payment: 20